Rheumatoid Arthritis
📧 Sign up to get email alerts when something new happens for Rheumatoid Arthritis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-08-24Clinical Trial Update: Evaluation of the Precision and Sensitivity of Tilmanocept Uptake Value (TUV) on Tc 99m Tilmanocept Planar Imaging [Phase 2]
Phase 2 trial evaluating the precision and sensitivity of Tilmanocept uptake value on Tc-99m Tilmanocept planar imaging in rheumatoid arthri…
-
FDA approval · 2023-08-17FDA Approved: OXAPROZIN — Supplemental Application (Dr. Reddy's Laboratories Limited)
The FDA approved a supplemental application for Oxaprozin submitted by Dr. Reddy's Laboratories Limited.
-
CLINICAL_TRIALS withdrawal · 2023-08-07Clinical Trial Update: MabionCD20® Compared to MabThera® and Rituxan® in Patients With Rheumatoid Arthritis [Phase 3]
Phase 3 trial comparing MabionCD20 to MabThera/Rituxan in rheumatoid arthritis was withdrawn.
-
CLINICAL_TRIALS trial_result · 2023-08-01Clinical Trial Update: Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males With Active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Non-radiographic Axial Spondyloarthritis [Phase 2]
This Phase 2 trial update reports results from a study evaluating the effect of Filgotinib on semen parameters in adult males with active rh…
-
FDA approval · 2023-07-19FDA Approved: ADALIMUMAB-ADBM — Supplemental Application (QUALLENT PHARMACEUTICALS HEALTH LLC)
The FDA approved a supplemental application for ADALIMUMAB-ADBM, a biosimilar of adalimumab from Quallent Pharmaceuticals Health LLC.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-07-18Clinical Trial Update: The Glucocorticoid Low-dose Outcome in RheumatoId Arthritis Study [Phase 4]
Phase 4 trial update on low-dose glucocorticoids in rheumatoid arthritis; results posted after completion.
-
CLINICAL_TRIALS trial_result · 2023-07-17Clinical Trial Update: Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors [Phase 3]
Phase 3 trial comparing otilimab (GSK3196165) to placebo and sarilumab in moderately to severely active rheumatoid arthritis patients with i…
-
CLINICAL_TRIALS trial_result · 2023-07-07Clinical Trial Update: This Study is to Investigate the Effect of Etanercept in Early Versus Delayed Referral for Management of Rheumatoid Arthritis Patients.
A completed clinical trial evaluating the effect of etanercept in early versus delayed referral for management of rheumatoid arthritis.
-
FDA approval · 2023-06-30FDA Approved: ADALIMUMAB-ADBM — Supplemental Application (QUALLENT PHARMACEUTICALS HEALTH LLC)
The FDA approved a supplemental application for the adalimumab biosimilar ADALIMUMAB-ADBM from Quallent Pharmaceuticals Health LLC.
-
CLINICAL_TRIALS trial_result · 2023-06-29Clinical Trial Update: The Effects of Mesenchymal Stem Cell Secretome in Rheumatoid Arthritis Patients [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating the effects of mesenchymal stem cell secretome in patients with rheumatoid arthritis has completed.
-
CLINICAL_TRIALS trial_result · 2023-06-22Clinical Trial Update: Subunit Vaccine Against Herpes Zoster in RA Patients Treated With JAK-inhibitors (VACCIMIL-ZOSTER) [Phase 4]
Phase 4 trial update on a subunit herpes zoster vaccine in rheumatoid arthritis patients treated with JAK inhibitors; study completed.
-
CLINICAL_TRIALS trial_result · 2023-06-18Clinical Trial Update: Effects of Social Networking on Chronic Disease Management in Arthritis [Phase 2, Phase 3]
A Phase 2/Phase 3 trial examining how social networking impacts chronic disease management in rheumatoid arthritis has completed.
-
FDA approval · 2023-06-14FDA Approved: ABRILADA — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved a supplemental application for ABRILADA (adalimumab-afzb) submitted by Pfizer Laboratories Div Pfizer Inc to update the labelin…
-
FDA approval · 2023-06-07FDA Approved: MELOXICAM — Original Application (XLCare Pharmaceuticals, Inc.)
The FDA approved the original application for MELOXICAM (meloxicam), a generic version manufactured by XLCare Pharmaceuticals, Inc., under A…
-
FDA approval · 2023-05-23FDA Approved: ADALIMUMAB — Original Application (CELLTRION USA, Inc.)
FDA approved ADALIMUMAB-AATY from CELLTRION USA, Inc. as a biosimilar to adalimumab under an Original Application for the same indications a…
-
FDA approval · 2023-05-18FDA Approved: ADALIMUMAB-ADBM — Supplemental Application (QUALLENT PHARMACEUTICALS HEALTH LLC)
FDA approved a supplemental application for ADALIMUMAB-ADBM, a biosimilar to adalimumab, from QUALLENT PHARMACEUTICALS HEALTH LLC.
-
CLINICAL_TRIALS trial_result · 2023-05-18Clinical Trial Update: Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN) [Phase 4]
Phase 4 clinical trial update for biologics targeting rheumatoid arthritis pain; study completed.
-
FDA label_change · 2023-05-10FDA Approved: METHYLPREDNISOLONE ACETATE — Supplemental Application (Sandoz Inc.)
FDA approved a supplemental application for methylprednisolone acetate by Sandoz Inc.
-
CLINICAL_TRIALS trial_result · 2023-05-08Clinical Trial Update: Effects of Abatacept on Myocarditis in Rheumatoid Arthritis [Phase 4]
Phase 4 trial investigating abatacept for myocarditis in rheumatoid arthritis was terminated; results posted in 2023.
-
FDA approval · 2023-05-05FDA Approved: IBUPROFEN — Supplemental Application (Winco Foods, LLC)
The FDA approved a supplemental application for a generic ibuprofen product developed by Winco Foods, LLC.
-
FDA approval · 2023-05-05FDA Approved: HYDROXYCHLOROQUINE SULFATE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application for hydroxychloroquine sulfate from Sun Pharmaceutical Industries, Inc., updating the approval for t…
-
CLINICAL_TRIALS trial_result · 2023-04-28Clinical Trial Update: Trial With HuMax-CD4 in Participants With Rheumatoid Arthritis (RA) Failing Treatment With Methotrexate (MTX) and a TNF-alpha Blocker [Phase 2, Phase 3]
Phase 2/3 trial of HuMax-CD4 in rheumatoid arthritis patients who failed methotrexate and TNF blockers was terminated.
-
CLINICAL_TRIALS trial_result · 2023-04-27Clinical Trial Update: Tofacitinib in the Treatment of Rheumatoid Arthritis-related Interstitial Lung Disease. [Phase 2]
Phase 2 clinical trial update investigating tofacitinib for rheumatoid arthritis-related interstitial lung disease (RA-ILD).
-
CLINICAL_TRIALS trial_result · 2023-04-25Clinical Trial Update: Role of Nitazoxanide and Escitalopram in Patients With Rheumatoid Arthritis [Phase 3]
Phase 3 trial update on nitazoxanide and escitalopram in patients with rheumatoid arthritis.
-
CLINICAL_TRIALS trial_result · 2023-04-25Clinical Trial Update: Baricitinib, Methotrexate as Monotherapy or Combination in the Treatment of Rheumatoid Arthritis - an Open Label Randomized Clinical Trial [Phase 4]
An open-label randomized Phase 4 clinical trial evaluating baricitinib, methotrexate as monotherapy or in combination for rheumatoid arthrit…